Improvements in Psoriasis-Related Work Productivity with Tildrakizumab: Results from a Phase 4 Real-World Study in Patients with Moderate-to-Severe Plaque Psoriasis

Tina Bhutani; John Koo; Jayme Heim; Neal Bhatia; Jacob Mathew; Thomas Ferro; J Gabriel Vasquez

doi:10.1007/s13555-024-01131-1

Improvements in Psoriasis-Related Work Productivity with Tildrakizumab: Results from a Phase 4 Real-World Study in Patients with Moderate-to-Severe Plaque Psoriasis

Dermatol Ther (Heidelb). 2024 Apr;14(4):1019-1025. doi: 10.1007/s13555-024-01131-1. Epub 2024 Apr 4.

Authors

Tina Bhutani¹, John Koo², Jayme Heim³, Neal Bhatia⁴, Jacob Mathew⁵, Thomas Ferro⁵, J Gabriel Vasquez³

Affiliations

¹ University of California San Francisco Health, 515 Spruce Street #101, San Francisco, CA, 94118, USA. tina.bhutani@ucsf.edu.
² University of California San Francisco Health, 515 Spruce Street #101, San Francisco, CA, 94118, USA.
³ West Michigan Dermatology, Grandville, MI, USA.
⁴ Therapeutics Clinical Research, San Diego, CA, USA.
⁵ Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA.

Abstract

Introduction: Plaque psoriasis is a chronic condition that may impact patients' work productivity. Tildrakizumab, an interleukin-23 p19 inhibitor, is approved for treatment of moderate-to-severe plaque psoriasis in adults. However, the effect of tildrakizumab treatment on work productivity in patients with psoriasis is not well characterized.

Methods: In this multicenter, open-label, uncontrolled phase 4 study (NCT03718299), patients with moderate-to-severe plaque psoriasis received tildrakizumab 100 mg at week 0, week 4, and every 12 weeks thereafter through week 52. Patients completed the Work Productivity and Activity Impairment Questionnaire: Psoriasis (WPAI:PSO) at baseline and every 12 weeks from week 16 through week 64. The following four domains of the WPAI:PSO were examined: absenteeism (percentage of time missed from work due to psoriasis), presenteeism (percentage reduction of productivity while at work due to psoriasis), total activity impairment (percentage impairment in activities other than work due to psoriasis), and total work productivity impairment (total percentage of work impairment from both absenteeism and presenteeism due to psoriasis). Missing data were not imputed.

Results: Of the 55 patients enrolled, 31 patients completed all domains of the WPAI:PSO at week 64. From baseline to week 64, respectively, mean ± standard deviation (SD) scores improved for presenteeism (20.5 ± 21.7 to 2.6 ± 5.8; P < 0.001), total activity impairment (29.5 ± 26.6 to 4.4 ± 9.4; P < 0.001), and total work productivity impairment (20.9 ± 22.2 to 2.6 ± 5.8; P < 0.001). The mean ± SD score for absenteeism decreased from 1.1 ± 5.7 at baseline to 0.0 ± 0.0 at week 64, but this change was not statistically significant.

Conclusion: Tildrakizumab treatment mitigated work productivity loss due to psoriasis as measured by the presenteeism, total activity impairment, and total work productivity impairment domains of the WPAI:PSO.

Trial registration: ClinicalTrials.gov identifier, NCT03718299.

Keywords: Psoriasis; Tildrakizumab; Work productivity.

Associated data

ClinicalTrials.gov/NCT03718299